AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Insight Partners hit by cyber attack with possible data leaks
2
CyberArk’s surge, Wiz and Cato prepare for IPOs: Israeli cyber firms ready for the next big move
3
How Intel ruined an Israeli startup it bought for $2B—and lost the AI race
4
Riskified cuts staff as struggles continue
5
Techtonic to invest over $140 million to build one of Israel's largest data centers
More news

Teva

20 stories about Teva
קור שולץ מנכ"ל טבע 9.11.19

Teva Faces U.S. Criminal Probe on Opioid-Related Distribution, Report Says

27.11.19|CTech
The Israeli drugmaker is one of six companies to receive subpoenas from federal investigators, the Wall Street Journal reported Tuesday
מטה חברת טבע תרופות

Teva in Talks With U.S. DoJ to End Price-Fixing Probe, Report Says

26.11.19|CTech
The Israeli drugmaker, along with several other companies investigated in the matter, have been holding talks on the subject for the past six months, Bloomberg reported
קור שולץ מנכ"ל טבע 9.11.19

Teva Raises $2.1 Billion in Debt Tender Offer

20.11.19|Sophie Shulman
Teva originally aimed to raise $1.5 billion, to redeem previous debentures it raised to finance the $40.5 billion acquisition of Actavis in 2016
אתר טבע כפר סבא

Teva’s Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing

17.11.19|Navit Zomer
The Israeli drugmaker’s manufacturing facility in Kfar Saba, already experienced with manufacturing cash cow Copaxone, will oversee the process of filling the syringes with the biological drug and also conduct quality control tests
מטה חברת טבע תרופות

Teva Up 25% on NYSE Since Third Quarter Reports

17.11.19|Sophie Shulman
The Israeli drugmaker closed 8.74% up on Friday after a Cleveland County District judge reduced the fine placed on Johnson and Jonhson in Oklahoma by $107 million, citing a math error made in the original ruling
קור שולץ מנכ"ל טבע 9.11.19

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19|Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
קור שולץ מנכ"ל טבע 9.11.19

Teva Announces $1.5 Billion Debt Tender Offer

10.11.19|Sophie Shulman
On Thursday, the Israeli drugmaker published its third quarter reports for 2019, reporting it had cut down its net debt to $25.7 billion
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Quarterly Report Meets Analyst Expectations

07.11.19|Sophie Shulman
The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion
מטה חברת טבע תרופות

Teva Overcomes One Hurdle, Many Still Ahead

23.10.19|Hezi Sternlicht
The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
מטה חברת טבע תרופות

Teva Announces $23.25 Billion Opioid Abuse Settlement Agreement

22.10.19|Lilach Baumer
Teva announced on Monday a settlement with both Cuyahoga and Summit counties of Ohio, averting the trial scheduled for later that day, and an agreement in principle for a global settlement framework
מטה חברת טבע תרופות

Teva Consortium Fails to Reach Opioid Abuse Settlement, Report Says

20.10.19|CTech
A $50 billion offer made last week by Teva and the three largest drug distributors in the U.S. does not seem to have panned out, Reuters reported Friday
מטה חברת טבע תרופות

Teva Part of $50 Billion Opioid Settlement Deal, Report Says

17.10.19|Hezi Sternlicht
Teva, a second drugmaker, and the three largest drug distributors in the U.S. have agreed with multiple states on a settlement framework ahead of Monday’s trial, the New York Times reported Thursday
אתר טבע כפר סבא

Teva Makes $15 Billion Settlement Offer in U.S. Opioid Case, Report Says

16.10.19|Hezi Sternlicht
The Israeli drugmaker and several other drug distributors are set to face around 2,500 lawsuits related to the U.S. opioid abuse epidemic in just a week at a Cleveland, Ohio federal court
מטה חברת טבע תרופות

Judge Rejects Teva’s Request to Be Tried Separately in U.S. Opioid Case, Report Says

13.10.19|CTech
Teva made a last minute attempt to be tried separately in opioid abuse damages case set to be held on October 21 in federal court in Cleveland, Ohio
מטה חברת טבע תרופות

Teva Part of Consortium Looking to Participate in Purdue Pharma's Bankruptcy, Report Says

02.10.19|CTech
Five of the drugmakers currently battling opioid abuse damages lawsuits in the U.S. are looking to achieve a global settlement through Purdue's bankruptcy case, the Wall Street Journal reported Monday
רון מירון מנכ"ל חברת אייסיקיור

Cannabis Company InnoCan Lists on the Canadian Securities Exchange

26.09.19|Tzally Greenberg
The Israel-based company listed 4% of its shares and raised $1.5 million at a $12.08 million company valuation
חברת תרופות אלרגן

Allergan Says Teva Bears Sole Liability for Actavis' Actions

02.09.19|Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
אתר טבע כפר סבא

Teva to Close Missouri Plant, Report Says

29.08.19|Tzally Greenberg
Teva’s manufacturing plant in Israeli city Netanya is also slated for final closure in early 2020, as part of the company’s reorganization plan
מטה חברת טבע תרופות

Teva Crashes Following Purdue Pharma $10-$12 Billion Settlement Reports

28.08.19|Lilach Baumer
Teva, like many other opioid manufacturers operating in the U.S., will be facing multiple opioid abuse-related lawsuits at a trial set to start in October at an Ohio federal court
אתר טבע כפר סבא

Teva Faces New Opioid-Related Lawsuit in West Virginia

25.08.19|Hezi Sternlicht
The lawsuit seems to be unrelated to the trial set to start against Teva and other opioid manufacturers in October in Ohio federal court
Previous ArticlesMore Articles